CENTENE CORPORATION
Last · NYSE$70.16+1.30 (+1.89%)close · yahoo · 13h ago
Market cap$34.66B494.0M sh
P/E · TTM-6.1fwd 13.1 · eps -10.44 · loss
Beta1.13vs S&P 500
Div yield0.00%annual · TTM
52w range
$31.63$70.37
Volume3.8Msession
| Revenue | $202.9B |
|---|---|
| Operating income | $3.1B |
| Net income | $2.6B |
| Free cash flow | $9.0B |
| Operating margin | 1.5% |
| Net margin | 1.3% |
| Return on equity | 11.7% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-17
- Medical Cost Trend
- Medicaid Rate Adequacy
- Marketplace Morbidity
- Obbba Risk
- Magellan Divestiture
- High Debt
- Government Program Concentration
Red flags
- Net loss attributable to Centene was $6.674 billion in 2025 versus $3.305 billion of net income in 2024; diluted EPS fell to $(13.53) from $6.31.
- Management reported accelerated medical-cost trend in 2025, including higher-than-expected Medicaid costs and a materially higher implied Marketplace morbidity that reduced expected 2025 risk-adjustment revenue.
- Centene recorded $513 million of pre-tax, or $389 million after-tax, non-cash impairment charges related to the pending Magellan Health divestiture.
- Total debt was $17.401 billion at December 31, 2025, including $2.000 billion under the term loan facility, while 2025 share repurchases totaled $448 million despite the net loss.
- The company highlights uncertainty around claims liability estimates and states that relatively small HBR changes can create significant changes in financial results.
- Legal and regulatory exposure includes CMS and Marketplace risk adjustment, minimum MLR, prior authorization, claims-payment, network adequacy and cybersecurity matters; accrued legal and regulatory amounts were not material as of the report date, but potential losses may be difficult to estimate.
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.10
Est. revenue
46.9B